Cegedim Sa · EURONEXT:ALCGM

Cegedim Sa — FY2012 Earnings Presentation

58 slides from Cegedim Sa's earnings presentation, Mar 5, 2013

  1. Slide 1: 2012 Financial Results

    2012 Financial Results March 5, 2013 Boulogne-Billancourt

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward- looking statements involve risk and uncertainty. Forward-looking g statements represent p the company's judgment reg

  3. Slide 3: Distribution notice and copyright

    This document should not be distributed with hout Cegedim authorization – Copyright 2013 3

  4. Slide 4: Key Take Aways

     Key Take Aways This document should not be distributed with hout Cegedim authorization – Copyright 2013 4

  5. Slide 5: Robust Performance, Better than Expected

     Robust Performance, Better than t Expected This document should not be distributed with hout Cegedim authorization – Copyright 2013 5

  6. Slide 6: The Changing World of the Healthcare

     The Changing World of the Healthcare H This document should not be distributed with hout Cegedim authorization – Copyright 2013 6

  7. Slide 7: Market Opportunities to Drive Transformation

     Market Opportunities to Drivee Transformation This document should not be distributed with hout Cegedim authorization – Copyright 2013 7

  8. Slide 8: CRM & Strategic Data

     CRM & Strategic Data This document should not be distributed with hout Cegedim authorization – Copyright 2013 8

  9. Slide 9: The Industry Direction: Generic Conversions

     The Industry Direction: Geneeric Conversions The visibility of the growth trend d after the patent cliff is increasing This document should not be distributed with hout Cegedim authorization – Copyright 2013 9

  10. Slide 10: Shift on Spend Allocation

     Shift on Spend Allocation Spend p allocation is shifting g from Fa ace-to-Face to alternative channels This document should not be distributed with hout Cegedim authorization – Copyright 2013 10

  11. Slide 11: Shift in Spending by Companies Size

     Shift in Spending by Compannies Size Medium-Smaller Companies s are Increasing their Spend A New Markett for Cegedim This document should not be distributed with hout Cegedim authorization – Copyright 2013 11

  12. Slide 12: Healthcare Data become cornerstone

     Healthcare Data become cornnerstone OneKey Over 8m HCPs Digital data #1 collection Platform The most complete 69 countries HCP database All decision-makers involved in prescription & buying process Pricing Enable effective e Non rep dependent targeting an nd profiling Pay per usage / app Product I

  13. Slide 13: Tremendous Market Opportunities Expand with New product

     Tremendous Market Opportuunities 9 Expand with New product 9 Digital 9 Targeting 9 New technology (Windows 8) 9 Expand to New Segment 9 Compliance p 9 Medical Device 9 Expand Geographicly 9 Emerging Countries This document should not be distributed with hout Cegedim authorization – Copyright 2013

  14. Slide 14: MI Touch on Windows 8 and IOS

     MI Touch on Windows 8 and IOS This document should not be distributed with hout Cegedim authorization – Copyright 2013 14

  15. Slide 15: Docnet: The Credible Alternative to Email

     Docnet: The Credible Alternaative to Email Docnet 4 countries launched in 2012 Communityy members are OneKey y validated A social community 8 new countries in 2013 dedicated for physicians Including France, UK, … Pharma Cies can communicate digitally with physicians The plac ce to be More than 16,

  16. Slide 16: Compliance: Great Potential in US and EU

     Compliance: Great Potential in US and EU AggregateSpend360 Worldwide e leader in More than Cegedim compliance transparenc cy reporting 50 solution for transparency Customers Solution for medical affairs 14 Multi-coun ntry deals new customers in Europe in 2012 Sunshine Act: A August 1, 2013 startin

  17. Slide 17: Emerging Market: Key Market for Pharma Cies

     Emerging g g Market: Key et for Pharma Cies y Marke Key Drivers Main markets m 16% • Favorable China, Brazil, Russia demographics Of CRM & Strategic Data Revenue in 2012 • Ascension of g global middle class • Aging population China: Groww expected p • Government G support at 15--20% for expanding

  18. Slide 18: Expand to new Segments

     Expand to new Segments This document should not be distributed with hout Cegedim authorization – Copyright 2013 18

  19. Slide 19: Solutions Platform for Life Sciences Cies

     Solutions Platform for Life Scciences Cies This document should not be distributed with hout Cegedim authorization – Copyright 2013 19

  20. Slide 20: Healthcare Professionals

     Healthcare Professionals This document should not be distributed with hout Cegedim authorization – Copyright 2013 20

  21. Slide 21: Market Opportunities

     Market Opportunities This document should not be distributed with hout Cegedim authorization – Copyright 2013 21

  22. Slide 22: Market Opportunity: Patient Portal

     Market Opportunity: y Patient Portal Patient Already launched Reduce bu ureaucracy in Internet platform that allows patients and Spain physicians to communicate using an easy and secure Set appointments channel Alerts Launched in France Develop a hea althcare plan in 2013 Follow up on treatment In

  23. Slide 23: Solutions Platform for Healthcare Professionals

     Solutions Platform for Healthhcare Professionals This document should not be distributed with hout Cegedim authorization – Copyright 2013 23

  24. Slide 24: Insurance Companies

     Insurance Companies This document should not be distributed with hout Cegedim authorization – Copyright 2013 24

  25. Slide 25: Market Opportunities

     Market Opportunities This document should not be distributed with hout Cegedim authorization – Copyright 2013 25

  26. Slide 26: Generalization of the third-party payments

     Generalization of the third-paarty payments French Government wants that the GP should s be able to offer its patients the full third-party third party payment (manndatory and complementary) This document should not be distributed with hout Cegedim authorization – Copyright 2013 26

  27. Slide 27: Solutions Platform for Insurance Companies

     Solutions Platform for Insuraance Companies This document should not be distributed with hout Cegedim authorization – Copyright 2013 27

  28. Slide 28: E-business: A Promising Activity

     E-business: A Promising Acttivity 9 A network of 100,000 , online members 9 300 million exchanged electronic d documents t 9 1,000 large e-invoicing projects 9 Client references worldwide and in all sectors This document should not be distributed with hout Cegedim authorization – Copyright 2013 28

  29. Slide 29: SEPA (Single Euro Payment Area)

     SEPA (Single Euro Payment Area) 9 Cegedim g designed g and implemented p a range g of solutions and services in order to facilitate and optimize migration to SEPA S direct debit 9 Cegedim C di also l provides id new electronic l t i paymentt services, i th SEPA direct the di t debit d bit 9 Market

  30. Slide 30: Conclusion

     Conclusion This document should not be distributed with hout Cegedim authorization – Copyright 2013 30

  31. Slide 31: Financial performance better than expected

    Financial performance better than expected Robust performance in n the second half of 2012

  32. Slide 32: 2012 Key figures

     2012 Key figures This document should not be distributed with hout Cegedim authorization – Copyright 2013 32

  33. Slide 33: A resilient top line performance

     A resilient top line performannce 9 2012 Consolidated Group p Revenue 9 2012 L-f-L Revenue Growth Periode L‐f‐L Q1 0.3% Q2 (5.2%) Q3 1.4% Q4 0.3% This document should not be distributed with hout Cegedim authorization – Copyright 2013 33

  34. Slide 34: 2012 Consolidated P&L From revenue to operating profit

     2012 Consolidated P&L From revenue r to operating profit in € millions 2012 2011 % change Revenue 921.8 911.5 1.1% Capitalized production 48.4 47.1 2.8% Purchases P h used d (111.5) (111 5) (105.6) (105 6) 5.6% 5 6% External expenses (234.7) (240.2) (2.3%) Payroll costs (449.8) (442.2) 1.7% Oth (P

  35. Slide 35: Robust Performance in the H2 2012

     Robust Performance in the H2 H 2012 in € millions H2 2012 H2 2011 % change Revenue 468,5 452.9 3.4% Capitalized production 23.6 24.6 (4.1%) Purchases h used d ((59.4)) ((56.6)) 4.8% % External expenses (115.6) (118.6) (2.6%) Payroll costs (221.1) (216.5) 2.1% O h (Provision, Others (P i i TTaxes,

  36. Slide 36: CRM & Strategic Data: Margin growth in H2 2012

     CRM & Strategic Data: Margin growth in H2 2012 This document should not be distributed with hout Cegedim authorization – Copyright 2013 36

  37. Slide 37: Healthcare professional: Robust growth in revenue and margin

     Healthcare professional: Robustt growth in revenue and margin This document should not be distributed with hout Cegedim authorization – Copyright 2013 37

  38. Slide 38: Insurance & Services: Solid Growth

     Insurance & Services: Solid Growth G 9 EBITDA* and EBIT* increased over 3 ye years by y more than 70% This document should not be distributed with hout Cegedim authorization – Copyright 2013 38

  39. Slide 39: Well-Balanced and Diversified Revenue Mix

     Well-Balanced and Diversifieed Revenue Mix 9 Revenue Breakdown as of December 2012 Diversified revenue mix provide stable revenue base 9 Revenue Visibility 9 Low Customer Concentration ƒ Multi-Brand Strategy ƒ First client: 4.6% of Group revenue ƒ Strongg recurring g revenue model ƒ Topp 5 client:

  40. Slide 40: 2012 Consolidated P&L From operating profit to net profit

     2012 Consolidated P&L From operating o profit to net profit in € millions 2012 2011 Δ EBIT (34 8) (34.8 8 75 9 75.9 ns n.s. Net cost of financial debt (44.1 1) (37.7) 17.0% Interest paid on loans Tax expenses (7 6 (7.6 6) (6 6) (6.6) 15 1% 15.1% decrease from €32.3m in 2011 to Consolidated net pro

  41. Slide 41: A cash-flow Generating Model

     A cash-flow Generating Modeel (in millions of euros) This document should not be distributed with hout Cegedim authorization – Copyright 2013 41

  42. Slide 42: 2012 Net Debt Evolution

     2012 Net Debt Evolution (in millions of euros) This document should not be distributed with hout Cegedim authorization – Copyright 2013 42

  43. Slide 43: Business Seasonality

     Business Seasonality 9 Traditionally higher sales on software at a the end of the year 9 Spending of remaining operating budget 9 More use of data and market research ini Q4 due to the reorganization of sales force organization of new campaign, force, campaign annual a reporting reporting,… This d

  44. Slide 44: 2012 Balance Sheet

     2012 Balance Sheet (in millions of euros) This document should not be distributed with hout Cegedim authorization – Copyright 2013 44

  45. Slide 45: Net Debt Situation

     Net Debt Situation 9 Capital p Structure 9 Gross Debt by y Source of Financing g 9 Net Debt and Gearing This document should not be distributed with hout Cegedim authorization – Copyright 2013 45

  46. Slide 46: Significant Liquidity Position

     Significant Liquidity Positionn (As of Dec. 2012) 9 Liquidity 9 Bank Covenants As of Dec. 2012 Total Draw Available Committed Facilites Revolving Credit Facilities €80m €30m €50m Cash & Cash Equivalent €43m ‐ €43m Group Other Committed Facilities €38m €21m €17m Total €161m €51m €110m m Covenant re

  47. Slide 47: Cegedim Strives for Realistic Group Targets

     Cegedim Strives for Realisticc Group Targets This document should not be distributed with hout Cegedim authorization – Copyright 2013 47

  48. Slide 48: Mid-Term Financial Goals

     Mid-Term Financial Goals Restore Profitability y 9 ƒ Restore profitability to 2009 level Increase Cash-Flow Cash Flow Generation 9 ƒ Increase cash conversion ratio Focus on Debt Reduction 9 ƒ Reach a leverage ratio of 2.0x Priority to Organic Growth 9 ƒ No acquisition in 2013 This document should

  49. Slide 49: Dividend Policy

     Dividend Policy This document should not be distributed with hout Cegedim authorization – Copyright 2013 49

  50. Slide 50: Margin Improvement target in 2013

     Margin Improvement target inn 2013(1) The target for FY 20133 is to achieve a slight increase in revenue com mbined with an increase of EBIT compared to 20012. (i.e. 50bps increase in EBIT margin) (1) These projections are as publicly disclosed on March 20 013. The fact that Cegedim includes these

  51. Slide 51: Strategy to Bond Refinancing: Move Step by Step

     Strategy to Bond Refinancingg: Move Step by Step This document should not be distributed with hout Cegedim authorization – Copyright 2013 51

  52. Slide 52: Appendix

    Appe endix

  53. Slide 53: Details of Covenant Calculation

     Details of Covenant Calculation 9 Details of Adjusted Net Financial Debt Calculation Senior Net Debt in € thousands Consolidated total debt (A) 529,712 Profit sharing due via “la participation et l’intéressement des salaries” (B) 10,296 Subordinated Shareholder Loans (C) 45,094 Total active cash (

  54. Slide 54: Keep in Touch with Cegedim

     Keep in Touch with Cegedim This document should not be distributed with hout Cegedim authorization – Copyright 2013 54

  55. Slide 55: Keep in Touch

     Keep in Touch 9The Half-Year Report p 9The Corporate p This Document includes the Overview 2012 first half-year financial This document provides a statements and the quick qu c su summary ayo on Ceged Cegedim’ss management report. clients, business, key drivers, key figures. It is updated regularl

  56. Slide 56: 2013 Financial Agenda

     2013 Financial Agenda This document should not be distributed with hout Cegedim authorization – Copyright 2013 56

  57. Slide 57: An Award Winning Company (2011-2012)

     An Award Winning Companyy (2011-2012) 9 Grand prix of Transparency ƒ “The prize have been awarded a in recognition for the best practices in regulated financial repo orting. It pay tribute to the listed French companies that have demonstrated d their ability to make use of the best financial commu

  58. Slide 58: We Welcome your questions and comments

    We we W elcome l your questions ti and d comments t Jan Eryyk UMIASTOWSKI Chief In n estment Officer nvestment Head of Investor Relations Janeryk Ja e yk.umiastowski@cegedim.com u asto s @ceged co www.ceegedim.com/finance TEL: +3 33 (0) 1 49 09 33 36

Cegedim — FY2012 Earnings Presentation on 6ix